UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 30, 2014
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
YES X
NO ___
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
YES X
NO ___
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):
Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES ____
NO X
At May 5, 2014, 6,378,718,293 shares of the issuer s voting common stock were outstanding.
Table of Contents
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income for the three months ended March 30, 2014 and March 31, 2013
Condensed Consolidated Statements of Comprehensive Income for the three months ended March 30, 2014 and March 31, 2013
Condensed Consolidated Balance Sheets as of March 30, 2014 and December 31, 2013
Condensed Consolidated Statements of Cash Flows for the three months ended March 30, 2014 and March 31, 2013
Notes to Condensed Consolidated Financial Statements
Review Report of Independent Registered Public Accounting Firm
36
Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
37
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
80
Item 4.
Controls and Procedures
80
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
81
Item 1A.
Risk Factors
81
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
82
Item 3.
Defaults Upon Senior Securities
82
Item 4.
Mine Safety Disclosures
82
Item 5.
Other Information
82
Item 6.
Exhibits
83
Signature
84
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)
March 30,
2014
March 31,
2013
Revenues
11,353
12,410
Costs and expenses:
Cost of sales(a)
2,045
2,263
Selling, informational and administrative expenses(a)
3,040
3,217
Research and development expenses(a)
1,623
1,710
Amortization of intangible assets
1,117
1,219
Restructuring charges and certain acquisition-related costs
58
131
Other deductions net
623
145
Income from continuing operations before provision for taxes on income
2,847
3,725
Provision for taxes on income
582
1,109
Income from continuing operations
2,265
2,616
Discontinued operations net of tax
73
149
Net income before allocation to noncontrolling interests
2,338
2,765
Less: Net income attributable to noncontrolling interests
15
Net income attributable to Pfizer Inc.
2,329
2,750
Earnings per common share basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.35
0.36
Discontinued operations net of tax
0.01
0.02
Net income attributable to Pfizer Inc. common shareholders
0.36
0.38
Earnings per common share diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.35
0.36
Discontinued operations net of tax
0.01
0.02
Net income attributable to Pfizer Inc. common shareholders
0.36
0.38
Weighted-average shares basic
6,389
7,187
Weighted-average shares diluted
6,476
7,269
Cash dividends paid per common share
0.26
0.24
(a)
Excludes amortization of intangible assets, except as disclosed in Note 9B. Goodwill and Other Intangible Assets: Other Intangible Assets.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months Ended
(MILLIONS OF DOLLARS)
March 30,
2014
March 31,
2013
Net income before allocation to noncontrolling interests
2,338
2,765
Foreign currency translation adjustments
(75
(292
Reclassification adjustments(a)
(62
(137
(292
Unrealized holding losses on derivative financial instruments
(58
(396
Reclassification adjustments for realized losses(b)
12
526
(46
130
Unrealized holding gains/(losses) on available-for-sale securities
108
(10
Reclassification adjustments for realized gains(b)
(99
(158
(168
Benefit plans: actuarial gains, net
22
Reclassification adjustments related to amortization(c)
49
151
Reclassification adjustments related to settlements, net(c)
21
55
Other
(17
97
59
325
Benefit plans: prior service credits and other
Reclassification adjustments related to amortization(c)
(18
(16
Reclassification adjustments related to curtailments, net(c)
(4
(9
Other
(1
(2
(23
(24
Other comprehensive loss, before tax
(138
(29
Tax provision/(benefit) on other comprehensive loss(d)
(17
176
Other comprehensive loss before allocation to noncontrolling interests
(121
(205
Comprehensive income before allocation to noncontrolling interests
2,217
2,560
Less: Comprehensive income attributable to noncontrolling interests
12
Comprehensive income attributable to Pfizer Inc.
2,210
2,548
(a)
Reclassified into Discontinued operations net of tax in the condensed consolidated statements of income.
(b)
Reclassified into Other deductions net in the condensed consolidated statements of income.
(c)
Generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, in the condensed consolidated statements of income. For additional information, see Note 10. Pension and Postretirement Benefit Plans.
(d)
See Note 5C. Tax Matters: Taxes on Items of Other Comprehensive Loss.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS OF DOLLARS)
March 30,
2014
December 31,
2013
(Unaudited)
Assets
Cash and cash equivalents
2,862
2,183
Short-term investments
31,019
30,225
Accounts receivable, less allowance for doubtful accounts
9,399
9,357
Inventories
6,066
6,166
Current deferred tax assets and other current tax assets
4,974
4,624
Other current assets
3,473
3,689
Total current assets
57,793
56,244
Long-term investments
15,822
16,406
Property, plant and equipment, less accumulated depreciation
12,347
12,397
Goodwill
42,467
42,519
Identifiable intangible assets, less accumulated amortization
38,122
39,385
Noncurrent deferred tax assets and other noncurrent tax assets
1,498
1,554
Other noncurrent assets
3,759
3,596
Total assets
171,808
172,101
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt
9,319
6,027
Accounts payable
2,546
3,234
Dividends payable
1,663
Income taxes payable
851
678
Accrued compensation and related items
1,758
1,792
Other current liabilities
10,315
9,972
Total current liabilities
24,790
23,366
Long-term debt
27,649
30,462
Pension benefit obligations, net
4,533
4,635
Postretirement benefit obligations, net
2,645
2,668
Noncurrent deferred tax liabilities
25,923
25,590
Other taxes payable
3,784
3,993
Other noncurrent liabilities
4,416
4,767
Total liabilities
93,740
95,481
Commitments and Contingencies
Preferred stock
32
33
Common stock
454
453
Additional paid-in capital
77,849
77,283
Treasury stock
(69,204
(67,923
Retained earnings
72,028
69,732
Accumulated other comprehensive loss
(3,390
(3,271
Total Pfizer Inc. shareholders equity
77,769
76,307
Equity attributable to noncontrolling interests
299
313
Total equity
78,068
76,620
Total liabilities and equity
171,808
172,101
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Three Months Ended
(MILLIONS OF DOLLARS)
March 30,
2014
March 31,
2013
Operating Activities
Net income before allocation to noncontrolling interests
2,338
2,765
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization
1,456
1,774
Asset write-offs, impairments and related charges
137
513
Gain associated with the transfer of certain product rights to an equity-method investment
(490
Deferred taxes from continuing operations
345
920
Deferred taxes from discontinued operations
Share-based compensation expense
143
189
Benefit plan contributions (in excess of)/less than expense
(99
71
Other non-cash adjustments, net
(294
(119
Other changes in assets and liabilities, net of acquisitions and divestitures
(1,091
(3,327
Net cash provided by operating activities
2,935
2,303
Investing Activities
Purchases of property, plant and equipment
(292
(202
Purchases of short-term investments
(8,721
(10,742
Proceeds from redemptions and sales of short-term investments
7,569
6,386
Net (purchases of)/proceeds from redemptions/sales of investments with original maturities of 90 days or less
1,500
(5,596
Purchases of long-term investments
(1,808
(2,246
Proceeds from redemptions and sales of long-term investments
1,454
1,444
Acquisitions of intangible assets
(6
(126
Other investing activities
206
156
Net cash used in investing activities
(98
(10,926
Financing Activities
Proceeds from short-term borrowings
1,031
Principal payments on short-term borrowings
(3
(1,031
Net proceeds from short-term borrowings with original maturities of 90 days or less
1,031
3,485
Proceeds from issuance of long-term debt(a)
2,624
Principal payments on long-term debt
(752
(2
Purchases of common stock
(1,197
(4,626
Cash dividends paid
(1,662
(1,735
Proceeds from exercise of stock options
425
642
Other financing activities
25
46
Net cash provided by/(used in) financing activities
(2,133
434
Effect of exchange-rate changes on cash and cash equivalents
(25
Net increase/(decrease) in cash and cash equivalents
679
(8,189
Cash and cash equivalents, beginning
2,183
10,081
Cash and cash equivalents, end
2,862
1,892
Supplemental Cash Flow Information
Non-cash transactions:
Exchange of subsidiary common stock (Zoetis) for the retirement of Pfizer commercial paper issued in 2013(b)
2,479
Exchange of subsidiary senior notes (Zoetis) for the retirement of Pfizer commercial paper issued in 2012(b)
992
Transfer of certain product rights to an equity-method investment(c)
1,233
Cash paid during the period for:
Income taxes
536
548
Interest
361
433
(a)
Includes $2.6 billion from the issuance of senior notes by Zoetis (our former Animal Health subsidiary), net of the $1.0 billion non-cash exchange of Zoetis senior notes for the retirement of Pfizer commercial paper issued in 2012. See Note 2A. Divestiture and Equity-Method Investments: Divestiture.
(b)
See Note 2A. Divestiture and Equity-Method Investments: Divestiture.
(c)
See Note 2B. Divestiture and Equity-Method Investments: Equity-Method Investments.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation and Significant Accounting Policies
A. Basis of Presentation
We prepared the condensed consolidated financial statements following the requirements of the U.S. Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted.
Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three months ended February 23, 2014 and February 24, 2013.
In the condensed consolidated statements of comprehensive income, we have revised the presentation of other comprehensive income/(loss) shown in prior periods for derivative financial instruments and available-for-sale securities, as certain items had been reported net.
On June 24, 2013, we completed the full disposition of our Animal Health business, Zoetis Inc. (Zoetis). On February 6, 2013, an initial public offering (IPO) of the Class A common stock of Zoetis was completed, pursuant to which we sold 99.015 million shares of Class A common stock of Zoetis, which represented approximately 19.8% of the total outstanding Zoetis shares. The operating results of this business are reported as Discontinued operations net of tax in the condensed consolidated statement of income for the three months ended March 31, 2013. Prior periods have been restated. For additional information, see Note 2A. Divestiture and Equity-Method Investments: Divestiture.
Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our condensed consolidated balance sheets and condensed consolidated statements of income.
The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2013 Annual Report on Form 10-K.
B. Adoption of New Accounting Standards
We adopted the following new accounting and disclosure standards as of January 1, 2014 and there were no impacts to our condensed consolidated financial statements:
A new standard that clarified the accounting for cumulative translation adjustment (CTA) upon derecognition of a group of assets that is a business or an equity-method investment within a foreign entity.
A new standard regarding the measurement of obligations resulting from joint and several liability arrangements that may include debt agreements, other contractual obligations and settled litigation or judicial rulings.
C. Fair Value
Our fair value methodologies depend on the following types of inputs:
Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).
Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs).
Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).
A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 2. Divestiture and Equity-Method Investments
A. Divestiture
Animal Health Business (Zoetis)
On June 24, 2013, we completed the full disposition of Zoetis. The full disposition was completed through a series of steps, including, in the first quarter of 2013, the formation of Zoetis and an IPO of an approximate 19.8% interest in Zoetis and, in the second quarter of 2013, an exchange offer for the remaining 80.2% interest.
In the first quarter of 2013:
Formation of Zoetis On January 28, 2013, our then wholly owned subsidiary, Zoetis, issued $3.65 billion aggregate principal amount of senior notes. Also, on January 28, 2013, we transferred to Zoetis substantially all of the assets and liabilities of our Animal Health business in exchange for all of the Class A and Class B common stock of Zoetis, $1.0 billion of the $3.65 billion of Zoetis senior notes, and an amount of cash equal to substantially all of the cash proceeds received by Zoetis from the remaining $2.65 billion of senior notes issued. The $1.0 billion of Zoetis senior notes received by Pfizer were exchanged by Pfizer for the retirement of Pfizer commercial paper issued in 2012, and the cash proceeds received by Pfizer of approximately $2.6 billion were used for dividends and stock buybacks.
Initial Public Offering (19.8% Interest) On February 6, 2013, an IPO of the Class A common stock of Zoetis was completed, pursuant to which we sold 99.015 million shares of Class A common stock of Zoetis (all of the Class A common stock, including shares sold pursuant to the underwriters' over-allotment option to purchase additional shares, which was exercised in full) in exchange for the retirement of approximately $2.5 billion of Pfizer commercial paper issued in 2013. The Class A common stock sold in the IPO represented approximately 19.8% of the total outstanding Zoetis shares. The excess of the consideration received over the net book value of our divested interest was approximately $2.3 billion and was recorded in Additional paid-in capital.
In the second quarter of 2013:
Exchange Offer (80.2% Interest) On June 24, 2013, we exchanged all of our remaining interest in Zoetis for Pfizer common stock.
The operating results of the Animal Health business are reported as Discontinued operations net of tax in the condensed consolidated statement of income for the three months ended March 31, 2013.
Total Discontinued Operations
The following table provides the components of Discontinued operations net of tax:
Three Months Ended
(MILLIONS OF DOLLARS)
March 30,
2014
March 31,
2013
Revenues
1,089
Pre-tax income from discontinued operations
200
Provision for taxes on income(a)
51
Income from discontinued operations net of tax
149
Pre-tax gain on disposal of discontinued operations
64
Benefit for taxes on income
(4
Gain on disposal of discontinued operations net of tax(b)
68
Discontinued operations net of tax
73
149
(a)
Includes a deferred tax expense of $7 million for the three months ended March 31, 2013.
(b)
For the three months ended March 30, 2014, represents post-close adjustments.
The net cash flows of our discontinued operations for each of the categories of operating, investing and financing activities are not significant for the three months ended March 31, 2013, except that financing activities include the cash proceeds from the issuance of senior notes by Zoetis.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
B. Equity-Method Investments
Investment in Hisun Pfizer Pharmaceuticals Company Limited (Hisun Pfizer)
On September 6, 2012, we and Zhejiang Hisun Pharmaceuticals Co., Ltd. (Hisun), a leading pharmaceutical company in China, formed a new company, Hisun Pfizer, 49% owned by Pfizer and 51% owned by Hisun, to develop, manufacture, market and sell pharmaceutical products, primarily branded generic products, predominately in China. In the first quarter of 2013, we and Hisun contributed certain assets to Hisun Pfizer. Our contributions constituted a business, as defined by U.S. GAAP, and in the first quarter of 2013, we recognized a pre-tax gain of approximately $490 million in Other deductions net, reflecting the transfer of the business to Hisun Pfizer (including an allocation of goodwill from our former Emerging Markets reporting unit as part of the carrying amount of the business transferred). Since we hold a 49% interest in Hisun Pfizer, we had an indirect retained interest in the contributed assets; as such, 49% of the gain, or $240 million, represented the portion of the gain associated with that indirect retained interest.
Investment in ViiV Healthcare Limited
On January 21, 2014, the European Commission approved Tivicay (dolutegravir), a product for the treatment of HIV-1 infection, developed by ViiV Healthcare Limited (ViiV), an equity method investee. This approval, in accordance with the agreement between GlaxoSmithKline plc and Pfizer, triggered a reduction in our equity interest in ViiV from 12.6% to 11.7% and an increase in GlaxoSmithKline plc s equity interest in ViiV from 77.4% to 78.3%, effective April 1, 2014. As a result, in the first quarter of 2014, we recognized a loss of approximately $36 million in Other deductions net.
Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
We can incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example:
In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and
In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization and optimization actions, workforce reductions and the expansion of shared services, including the development of global systems.
All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and research and development (R&D), as well as groups such as information technology, shared services and corporate operations. However, in 2014-2016, our primary activities are expected to be associated with our manufacturing plant network rationalization and optimization activities, and commercial property rationalization and consolidation.
At the end of 2013, we had substantially completed many of the initiatives launched in prior periods. In early 2014, we announced that we would be incurring costs in 2014-2016 related to new programs: our new global commercial structure reorganization and additional cost-reduction/productivity initiatives.
In 2014, we have the following initiatives underway:
Manufacturing plant network rationalization and optimization, where execution timelines are necessarily long. Our plant network strategy is expected to result in the exit of nine sites over the next several years. In connection with these activities, during 2014-2016, we expect to incur costs of approximately $450 million associated with prior acquisition activity and costs of approximately $1.5 billion associated with new non-acquisition-related cost-reduction initiatives.
New global commercial structure reorganization, which primarily includes the streamlining of certain functions, the realignment of regional locations and colleagues to support the businesses, as well as implementing the necessary system changes to support future reporting requirements. In connection with this reorganization, during 2014-2016, we expect to incur costs of approximately $350 million.
Other new cost-reduction/productivity initiatives, primarily related to commercial property rationalization and consolidation. In connection with these cost-reduction activities, during 2014-2016, we expect to incur costs of approximately $900 million.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
The costs expected to be incurred during 2014-2016, of approximately $3.2 billion in total, include restructuring charges, integration costs, implementation costs and additional depreciation asset restructuring. Of this amount, we expect that about a quarter of the charges will be non-cash.
Current-Period Key Activities
In the first quarter of 2014, we incurred approximately $164 million in cost-reduction and acquisition-related costs (excluding transaction costs) in connection with the aforementioned programs, primarily associated with our manufacturing and sales operations.
The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:
Three Months Ended
(MILLIONS OF DOLLARS)
March 30,
2014
March 31,
2013
Restructuring charges(a):
Employee terminations
30
(21
Asset impairments
103
Exit costs
13
Total restructuring charges
40
95
Integration costs(b)
18
36
Restructuring charges and certain acquisition-related costs
58
131
Additional depreciation asset restructuring recorded in our condensed consolidated statements of income as follows(c):
Cost of sales
74
33
Selling, informational and administrative expenses
11
Research and development expenses
91
Total additional depreciation asset restructuring
74
135
Implementation costs recorded in our condensed consolidated statements of income as follows(d):
Cost of sales
Selling, informational and administrative expenses
15
31
Research and development expenses
11
Total implementation costs
32
39
Total costs associated with acquisitions and cost-reduction/productivity initiatives
164
305
(a)
In the three months ended March 30, 2014, Employee terminations represent the expected reduction of the workforce by approximately 200 employees, mainly in manufacturing and sales.
The restructuring charges in 2014 are associated with the following:
For the three months ended March 30, 2014, the Global Innovative Pharmaceutical segment (GIP) ($2 million), the Global Established Pharmaceutical segment (GEP) ($7 million), Worldwide Research and Development and Medical ($1 million), manufacturing operations ($26 million) and Corporate ($4 million).
The restructuring charges in 2013 are associated with the following:
For the three months ended March 31, 2013, total operating segments ($13 million), Worldwide Research and Development and Medical ($2 million), manufacturing operations ($3 million) and Corporate ($77 million). In 2014, we revised our operating segments and are unable to identify these prior-period restructuring charges to the new individual segments.
(b)
Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes.
(c)
Additional depreciation asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
(d)
Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
10
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
The following table provides the components of and changes in our restructuring accruals:
(MILLIONS OF DOLLARS)
Employee
Termination
Costs
Asset
Impairment
Charges
Exit Costs
Accrual
Balance, December 31, 2013(a)
1,685
94
1,779
Provision
30
40
Utilization and other(b)
(115
(6
(25
(146
Balance, March 30, 2014(c)
1,600
73
1,673
(a)
Included in Other current liabilities ($1.0 billion) and Other noncurrent liabilities ($767 million).
(b)
Includes adjustments for foreign currency translation.
(c)
Included in Other current liabilities ($968 million) and Other noncurrent liabilities ($705 million).
Note 4. Other Deductions Net
The following table provides components of Other deductions net:
Three Months Ended
(MILLIONS OF DOLLARS)
March 30,
2014
March 31,
2013
Interest income(a)
(92
(95
Interest expense(a)
321
371
Net interest expense
229
276
Royalty-related income(b)
(248
(63
Certain legal matters, net(c)
694
(83
Gain associated with the transfer of certain product rights(d)
(490
Net gains on asset disposals(e)
(181
(26
Certain asset impairments and related charges(f)
115
398
Costs associated with the Zoetis IPO(g)
18
Other, net
14
115
Other deductions net
623
145
(a)
Interest income decreased in the first three months of 2014 due to lower cash equivalents and investment balances and lower investment returns. Interest expense decreased in the first three months of 2014 primarily due to the benefit of the conversion of some fixed-rate liabilities to floating-rate liabilities.
(b)
Royalty-related income increased in 2014 due to royalties earned on sales of Enbrel in the U.S. and Canada after October 31, 2013. On that date, the co-promotion term of the collaboration agreement for Enbrel in the U.S. and Canada expired, and we became entitled to royalties for a 36-month period.
(c)
In the first quarter of 2014, includes approximately $620 million for Neurontin-related matters (including off-label promotion actions and antitrust actions) and approximately $50 million for an Effexor-related matter. In the first quarter of 2013, primarily includes an $80 million insurance recovery related to a certain litigation matter. For additional information, see Note 12A. Commitments and Contingencies: Legal Proceedings.
(d)
Represents the gain associated with the transfer of certain product rights to Hisun Pfizer, our 49%-owned equity-method investment in China. For additional information, see Note 2B. Divestiture and Equity-Method Investments: Equity-Method Investments.
(e)
In the first quarter of 2014, primarily includes gains on sales of product rights (approximately $70 million) and gains on sales of investments in equity securities (approximately $95 million).
(f)
In the first quarter of 2014, includes an intangible asset impairment charge of $114 million, virtually all of which relates to an in-process research and development (IPR&D) compound for the treatment of skin fibrosis. The intangible asset impairment charge for the first quarter of 2014 is associated with Worldwide Research and Development and reflects, among other things, the impact of changes to the development program. In the first quarter of 2013, includes an intangible asset impairment charge of $394 million, all of which relates to developed technology rights for use in the development of bone and cartilage. The intangible asset impairment charge for 2013 is associated with the Global Innovative Pharmaceutical segment and reflects, among other things, updated commercial forecasts.
(g)
Costs incurred in connection with the IPO of an approximate 19.8% ownership interest in Zoetis. Includes expenditures for banking, legal, accounting and similar services. For additional information, see Note 2A. Divestiture and Equity-Method Investments: Divestiture.
The asset impairment charges included in Other deductions net for the first three months of 2014 virtually all relate to identifiable intangible assets and are based on estimates of fair value.
11
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
The following table provides additional information about the intangible assets that were impaired during the first three months of 2014 in Other deductions net:
Fair Value(a)
Three Months Ended March 30, 2014
(MILLIONS OF DOLLARS)
Amount
Level 1
Level 2
Level 3
Impairment
Intangible assets IPR&D(b)
79
79
114
Total
79
79
114
(a)
The fair value amount is presented as of the date of impairment, as this asset is not measured at fair value on a recurring basis. See also Note 1C. Basis of Presentation and Significant Accounting Policies: Fair Value.
(b)
Reflects intangible assets written down to fair value in the first three months of 2014. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then we applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product and the impact of technological risk associated with IPR&D assets; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.
Note 5. Tax Matters
A. Taxes on Income from Continuing Operations
Our effective tax rate for continuing operations was 20.4% for the first quarter of 2014, compared to 29.8% for the first quarter of 2013. The lower effective tax rate for the first quarter of 2014 in comparison with the same period in 2013 was primarily due to the favorable impact of the resolution in the first quarter of 2014 of certain tax positions, pertaining to prior years, primarily with various foreign tax authorities, and from the expiration of certain statutes of limitations, the non-recurrence of the unfavorable tax impact associated with the non-deductibility of the goodwill derecognized and the jurisdictional mix of the other intangible assets divested as part of the transfer of certain product rights to our 49%-owned equity-method investment, as well as the change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business, partially offset by the expiration of the U.S. research and development (R&D) tax credit on December 31, 2013. For additional information about the transfer of certain product rights, see Note 2B. Divestiture and Equity-Method Investments: Equity-Method Investments.
B. Tax Contingencies
We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.
The United States is one of our major tax jurisdictions, and we are regularly audited by the U.S. Internal Revenue Service (IRS):
With respect to Pfizer Inc., tax years 2009 and 2010 are currently under audit. Tax years 2011-2014 are open, but not under audit. All other tax years are closed.
In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Canada (2004-2014), Japan (2013-2014), Europe (2007-2014, primarily reflecting Ireland, the United Kingdom, France, Italy, Spain and Germany), Latin America (1998-2014, primarily reflecting Brazil and Mexico) and Puerto Rico (2009-2014).
12
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
C. Taxes on Items of Other Comprehensive Loss
The following table provides the components of the tax provision/(benefit) on Other comprehensive loss: